Skip to content

EyePoint, Inc. EYPT DURAVYU Direct Research And Development Expense

DURAVYU Direct Research And Development Expense at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.87M-60.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$37.75M+79.0%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$501K
LBR
LB Pharmaceuticals Inc Common StockLBRX
$1.18M-88.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.36M+51.4%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$57.07M+12.2%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept eypt:DURAVYUDirectResearchAndDevelopmentExpense.

The official record: EyePoint, Inc. ’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's duravyu direct research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's DURAVYU direct research and development expense?
EyePoint, Inc. (EYPT) reported DURAVYU direct research and development expense of $37.32M in Q4 2025.
How has EyePoint, Inc. 's DURAVYU direct research and development expense changed year-over-year?
EyePoint, Inc. 's DURAVYU direct research and development expense increased by 110.8% year-over-year, from $17.7M to $37.32M.
What is the long-term trend for EyePoint, Inc. 's DURAVYU direct research and development expense?
Over 2 years (2023 to 2025), EyePoint, Inc. 's DURAVYU direct research and development expense has grown at a 115.9% compound annual growth rate (CAGR), from $32.01M to $149.29M.
What does DURAVYU direct research and development expense mean?
Captures the specific costs directly attributable to the research and development of a primary product candidate or technology platform. Monitoring this helps investors track the capital intensity and progress of the company's most critical pipeline assets.